Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Intraluminal antibodies to macrophage migration inhibitory factor decrease substance P induced inflammatory changes

Katherine L Meyer-Siegler1, Pedro L Vera

  • 1Bay Pines Veterans Affairs Medical Center, Research and Development Service, Bay Pines, Florida 33744, USA. Katherine.Siegler@med.va.gov

The Journal of Urology
|September 17, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Modulation of persistent bladder pain in mice: The role of macrophage migration inhibitory factor, high mobility group box-1, and downstream signaling pathways.

Bladder (San Francisco, Calif.)·2024
Same author

MIF-Modulated Spinal Proteins Associated with Persistent Bladder Pain: A Proteomics Study.

International journal of molecular sciences·2024
Same author

Lumbosacral spinal proteomic changes during PAR4-induced persistent bladder pain.

Neuroscience letters·2023
Same author

Urothelial Oxidative Stress and ERK Activation Mediate HMGB1-Induced Bladder Pain.

Cells·2023
Same author

Bladder Oxidative Stress and HMGB1 Release Contribute to PAR4-Mediated Bladder Pain in Mice.

Frontiers in systems neuroscience·2022
Same author

Intravesical CD74 and CXCR4, macrophage migration inhibitory factor (MIF) receptors, mediate bladder pain.

PloS one·2021
Same journal

On the Memoryless Property in Markov Models for NMIBC Cost-Effectiveness Analysis.

The Journal of urology·2026
Same journal

Multi-institutional Assessment of Performance Metrics for MRI-targeted Transperineal Prostate Biopsy.

The Journal of urology·2026
Same journal

Urinary Supersaturation in a Randomized Trial among Individuals with Recurrent Nephrolithiasis comparing Empiric versus Selective Preventive Therapy: The URINE Trial.

The Journal of urology·2026
Same journal

The FDA Should Allow More BCG Strains into the US Market: How Recent Landmark Trials Expose a Regulatory Paradox.

The Journal of urology·2026
Same journal

Let's Shift the Focus from Death to Life after Fournier's Gangrene.

The Journal of urology·2026
Same journal

Endourology and Nephrolithiasis.

The Journal of urology·2026
See all related articles

Substance P (SP) triggers inflammation, but macrophage migration inhibitory factor (MIF) amplifies it. Blocking MIF with an antibody reduced SP-induced inflammation in the bladder and prostate, identifying MIF as a therapeutic target.

Area of Science:

  • Urology
  • Immunology
  • Neuroscience

Background:

  • Noxious stimuli trigger substance P (SP) release, causing neurogenic inflammation.
  • SP is short-lived, requiring other mediators like macrophage migration inhibitory factor (MIF) to sustain inflammation.
  • The bladder stores and releases MIF in response to SP, potentially amplifying inflammatory responses.

Purpose of the Study:

  • To investigate the role of MIF in SP-induced pelvic visceral inflammation.
  • To test the hypothesis that MIF amplifies inflammation initiated by SP.

Main Methods:

  • Rats' bladders were isolated and treated with saline or anti-MIF antibody.
  • Systemic SP or saline was administered.
  • Inflammatory cytokine expression and histological changes in the bladder and prostate were assessed.

Related Experiment Videos

Main Results:

  • SP increased proinflammatory gene expression in the bladder and prostate.
  • Intraluminal anti-MIF antibody significantly reduced SP-induced changes, including MIF levels, cyclooxygenase-2, nerve growth factor, c-fos, and edema.
  • SP increased bladder lumen MIF levels.

Conclusions:

  • MIF plays a significant role in acute pelvic visceral neurogenic inflammation.
  • Blocking MIF with an antibody effectively reduced SP-induced inflammation.
  • MIF is a potential therapeutic target for pelvic viscera inflammation.